论文部分内容阅读
目的观察依达拉奉联合奥扎格雷钠治疗进展性脑梗死(PCI)的疗效。方法对40例PCI患者用奥扎格雷钠80mg加入生理盐水250ml静脉滴注,2次/d,连用14d;依达拉奉30mg加入生理盐水100ml静脉滴注,2次/d,连用14d。在治疗前、后进行全国第四届脑血管病会议修定的NDS评分标准和Barthel指数(BI)评分;并与单用奥扎格雷钠的对照组比较。结果联合治疗组治疗14d时的NDS评分显著低于对照组(P<0.05);联合治疗组的显效率(75%)和有效率(92.5%)明显高于对照组(42.5%、80%)(P<0.05)。结论依达拉奉联合奥扎格雷钠治疗进展性脑梗死有显著疗效,无明显不良反应。
Objective To observe the therapeutic effect of edaravone and ozagrel on patients with progressive cerebral infarction (PCI). Methods 40 cases of PCI patients were treated with sodium ozagrel 80mg intravenously with normal saline 250ml twice a day for 14 days. Edaravone 30mg was added into 100ml normal saline intravenously once a day for 14 days. NDS score and Barthel index (BI) score revised at the Fourth National Conference on Cerebrovascular Diseases before and after treatment were compared with those of control group using ozagrel alone. Results The NDS score of the combined treatment group was significantly lower than that of the control group on the 14th day (P <0.05). The effective rate (75%) and effective rate (92.5%) in the combined treatment group were significantly higher than those in the control group (42.5%, 80% (P <0.05). Conclusion Edaravone combined with ozagrel sodium in the treatment of progressive cerebral infarction has a significant effect, no significant adverse reactions.